Series B co-led by Fast Track Initiative, DCI Partners, and 4BIO Capital Proceeds to accelerate development of LUCA's novel Mitochondria Isolation Technology (MIT) platform, IND-enabling activities
(0)
LUCA Science (Tokyo, Japan), a biotechnology company pioneering a novel class of mitochondrial therapeutics has announced the expansion of its international operations, with the establishment of a new wholly-owned subsidiary company in the United Kingdom.
LUCA Science UK will focus on research collaborations with the University of Oxford using LUCA Science s proprietary Mitochondria therapy in advancing treatment of intra-uterine growth restriction (IUGR) for mothers and babies. LUCA Science s CEO, Dr Rick Tsai, said We are very fortunate to be working with international experts: Professor Manu Vatish, academic obstetrician, and Professor Joanna Poulton, specialist in mitochondrial genetics. Establishing a subsidiary in the UK will allow us to tap into top local talent to build a research team collaborating with the University of Oxford to expand LUCA Science s existing portfolio.